Professional Documents
Culture Documents
www.theijs.com
REVIEW
University Department of Endo and Vascular Surgery, University Hospital ‘‘Sestre milosrdnice’’,
Vinogradska 29, 10000 Zagreb, Croatia
KEYWORDS Abstract Modern surgical treatment for aortic valve disease has undergone significant im-
Aortic valve provements in all areas of this procedure. Successful treatment strategies for cardiovascular
replacement; diseases have often been initiated and driven by surgeons. Radical excision of diseased tissue,
Stented aortic valve; repair and replacement strategies lead to long-term successful treatment of the underlying
Surgery diseases and clearly improved patient outcome. In highly developed nations, valve surgery will
be increasing applied in older people, with more co-morbidities and a higher incidence of con-
comitant coronary artery disease. Cardiovascular surgeons will be facing increased competi-
tion from the catheter-based procedures; these are already applied clinically, and their
numbers will rise in near future. Right now interventional cardiologists supported by some car-
diac surgeons are on their way to transform some conventional open surgical procedures into
catheter-based less invasive interventions, such as valve repair and replacement. Cardiovascu-
lar surgery is undergoing a rapid transformation; socio-economic factors and recent advances
in medical technology contribute to these changes. Further developments will come, and sur-
geons with all their expertise in the treatment of valvular heart disease need to be part of it.
Cardiovascular surgeons have to adapt the exciting new approaches of transapical and trans-
femoral transcatheter valve implantation techniques.
ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1743-9191/$ - see front matter ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijsu.2007.04.009
170 N. Hudorović
(a) subjective lack of symptoms of older patients who and restenosis within months of the procedure,2 and has
would like to avoid open heart surgery; been abandoned.
(b) the assumption of family physicians or cardiologists of Apparently new transcatheter aortic valve implantation
a prohibitive operative risk, especially in older patients techniques have been developed by different groups. The
with several severe co-morbidities. continuous efforts of the two cardiologists, Cribier and
Bonhoeffer, led to the first successful percutaneous aortic
In the second half of the 20th century, an unprece- and pulmonary valve implantation, which paved the way for
dented prolongation of human life has been observed. further implants and studies during the past 4 years.
Average life expectancy in the countries of the European Despite being at an early stage of development, several
Union (EU) rose almost 9 years from 1960 to 2000 (Fig. 1), devices have already been introduced into clinical practice
and the increase was most marked in less developed EU at selected centers. A number of different devices (maybe
countries. 20 or more) currently are under development. In parallel,
The surgeons will be treating an increasing number of several experimental studies on the in vivo function of new
aged people; The United States expects that the aged devices have been performed. Several of these studies deal
population (>65 years) will double by 2040; by that time with some technical aspects of transcatheter valve implan-
it will reach 77 million, more than a quarter of total US tation with special focus on the surgical therapy using
population. Cardiovascular consequences are obvious: de- a transapical approach.3e6
generative heart disease (aortic stenosis, mitral regurgita-
tion, heart failure, total AV block) will be encountered Materials and methods
more frequently than before, and surgery will assume ex-
ceedingly complex proportion in this population with multi-
In highly developed nations of Europe and North America,
focal atherosclerosis. This fact is well reflected in the
catheter interventions greatly outnumber the operative
recent European Survey by Bruce Keogh,1 where the major
treatment of coronary atherosclerosis (Figs. 2 and 3). The
increase has been observed in the segment of combined
growth of invasive cardiology does not remain limited to
CABG and valve procedures.
PTCA and stenting of the coronary arteries.
In view of increasing patient risk profiles, cardiovascular
Percutaneous balloon mitral valvotomy is already estab-
surgeons should eventually rethink their whole conven-
lished as a primary treatment of mitral stenosis,7 although
tional strategy. This may include the evaluation and
the same technique is very unsatisfactory in the treatment
eventually adoption of new technical developments such
of aortic stenosis. Hence, the concept of non-surgical valve
as transcatheter valve implantation techniques into routine
replacement has evolved. Extension to the aortic valve was
practice. Potential steps to minimize the risk of aortic valve
inevitable and was most probably behind the initial interest
surgery are obvious:
in the pulmonary valve, since percutaneous valve therapy
developed initially with aortic valve replacement, described
(a) a minimally invasive access avoiding sternotomy; in 1992 in a swine model.8 Early experimental work in
(b) valve implantation on the beating heart avoiding animals9e11 paved the way for use in man, but Cribier
cardiac arrest; et al.12 is credited with the first human percutaneous trans-
(c) off-pump valve implantation. catheter implantation of aortic valve prosthesis for calcific
aortic stenosis. Since then, many operators and teams,
Balloon aortic valvuloplasty had been used as an alter- both cardiological and surgical, throughout the world have
native approach to non-surgical candidates. However, this enthusiastically embarked on programs of non-invasive or
treatment was associated with a high mortality and minimally invasive aortic valve replacement. Several models
especially morbidity rate, and a high return of symptoms of stent-fixed valve have been developed and newer modifi-
cations are introduced almost on a daily basis.13
Figure 1 Life expectancy for men and women, EU 15, 1960e Figure 2 CABG procedures in the USA SRS database, 1993 to
2000. Source: Eurostar June 2002.
Aortic valve surgery 171
Figure 3 Decrease of CAB procedures in the UK. Source: United Kingdom Cardiac Surgical Register trends in cardiac surgery
1877e2001 (n Z 578,051).
In the initial procedures, the catheter-mounted valved Antegrade femoral venous route
stents were delivered into the aortic annulus by an antegrade
trans-septal approach, but this method was technically The antegrade femoral venous route has the advantage that
difficult to master, especially with regard to the ability to may allow passage of large-profile valved stents and an
accurate intra-annular positioning and was abandoned in favor antegrade crossing of the aortic valve. However, the severe
of a retrograde arterial method. Peripheral vascular access in disadvantages include a long and tortuous route from the
patients with diseased or small iliac-femoral vessels will be femoral vein to the aortic valve, necessity to cross and
a stumbling block in many elderly patients. Additionally, these dilate the atrial septum, and the need to cross the mitral
transcatheter-based methods have some other limitations valve with the potential to induce acute mitral insufficiency
which include risk of embolization due to pre-dilatation and by pushing against the anterior mitral leaflet. In high-risk
detachment or fragmentation of atherosclerotic plaques, patients the latter is often associated with severe reduction
migration of the valved stent, paravalvular leakage and, in cardiac output due to the creation of a high-grade mitral
probably, limited durability of the prosthesis.14,15 valve insufficiency.20
Up to now, percutaneous aortic valve insertion has
allegedly been carried out on a compassionate basis in Retrograde arterial route
patients considered to be ‘‘extremely high-risk’’ for surgical
aortic valve replacement. However, significant paravalvular The retrograde arterial approach requires retrograde cross-
regurgitation and early mortality characterize the experi- ing of the stenotic aortic valve and is limited to a low-
ence thus far, and this raises many questions about the profile system (24 F in diameter). Frequently it results in
indications and may have important ethical implications. vascular trauma,20 especially in older patients with their
Although the concept of percutaneous replacement of high incidence of peripheral artery as well as atheroscle-
heart valves appears promising, it is clear that this rotic disease in the thoracic and abdominal aorta.
technology is in its infancy with a manifest inability to
achieve consistent results, which have, up to now, failed to
meet the expectations.16 Transapical route
Percutaneous, catheter-based treatments of mitral
insufficiency, both by edge-edge repair and reduction of The transapical approach seems to offer many potential
posterior leaflet of the mitral valve via coronary sinus,17 are advantages including that the native valve is crossed in an
being explored, and one can assume that these develop- antegrade fashion; it permits a shorter and stiffer delivery
ments, heavily sponsored by industry, will lead to larger system for more precise positioning and placement of the
clinical trials in the near future. Pulmonary valve replace- stented bioprosthesis. In addition, the lateral minithora-
ment by catheter technique is already established in the cotomy and the transapical approach have been used by
pediatric population,18 and percutaneous aortic valve Freiburg group,21 as well as apico-aortic conduit implanta-
replacement is being developed.19 tions, both with and without extracorporeal circulation.
In recent years, three approaches have evolved as The study on 6 months’ follow-up results after transapi-
potential access routes to the aortic valve. cal aortic valve implantation by the group from Vancouver
172 N. Hudorović
is at the forefront of clinical application. They performed optimal results in comparison to the transfemoral ap-
the first successful human transapical aortic valve implan- proaches with their potential size limitations.
tations using an oversizing technique, starting in November
2005 on a compassionate-use basis in patients deemed as
having an excessive operative risk. Recently their initial re- Discussion
sults in seven patients have been published.6,22 The infor-
mation on persistently good valve function after hospital Development of valve prosthesis has been stagnant in the
discharge probably is the most important message from recent years, and no major breakthroughs are presently
this publication. Good valve function had already been visible. Durable mechanical valves still need anticoagula-
proven in patients receiving a 23 mm CribiereEdwards pros- tion and are prone to thrombosis and embolism; a truly
thesis via transfemoral approach from 2002 onwards by antithrombogenic mechanical valve has not been yet de-
Cribier (Fig. 4).23 veloped, in spite of the remarkable progress in heparin
The stringent application of the oversizing concept of bonding. Biological valves are still not durable, and are
2e3 mm by the Vancouver group, implanting a 26 mm pros- used in exceeding numbers, due to the aging population
thesis only, has led to more successful hemodynamic and being subjected to valve replacement. Recent statistics25
clinical outcomes. Further clinical studies under ethical show that in the UK almost half of those patients with aortic
approval for operable but high-risk patients are under way. valve replacement receive biological valves. Homografts,
The Lausanne group focuses on a specific device for left due to the difficulties in obtaining good valves, play a mini-
ventricular apical closure when using such new minimally mal role and their numbers are not expected to rise in the
invasive transapical techniques.24 The authors demon- future.
strated the effectiveness of device closure after transapical Surgeons are the most experienced physicians offering
access, with the occluder consisting of two square heads definitive treatment for aortic valve disease. To further
squeezing the ventricle wall in between them, sealing the direct the development, surgeons have to actively take part
ventricular defect. A third element, a semi rigid guide in the developments designing future joint inclusion criteria
wire, is secured to the device for driving the deployment. and performing comparative and eventually randomized
The superior results when using a cuffed device are clear clinical trials; in parallel, retraining with the new catheter-
indicators of a further technical development in this field. based techniques will be required. Last but not the least
Transapical access usually can be performed without prob- ‘‘the transapical approach may be the first clear pathway
lems when using Teflon reinforced purse-string sutures. for cardiovascular surgeons to acquire and use catheter-
Fragile tissue, however, may lead to technical difficulties, based and image-guidance skills, especially in the procedure
especially when closing larger holes while being off-pump starts to replace traditional surgical valve replacement in
in high-risk patients. higher risk patients’’.26
One of the most important aspects of the transapical Cardiovascular care is rapidly moving toward catheter-
approach is the unlimited feasibility even in the presence based technologies, and many cardiovascular surgeons are
of large sheaths, up to 30 F or more. With the help of stan- looking for ways to become involved. Endovascular tech-
dard purse-string sutures or a closure device, there is no niques are not currently part of the standard cardiovascular
real limitation on size. This will allow surgeons to implant surgeon’s practice, nor are catheter skills part of the
the most advanced, possibly cuffed prosthesis to achieve required residency training program curriculum.27
Endoluminal grafting for aortic valvular disease is an
involved process and cannot be learned in a weekend or
even in a month-long course. In addition to wire skills,
vascular access for aortic valve procedures is an important
consideration, and involves skills such as retroperitoneal
conduits, management of delivery complications and bra-
chialefemoral wires. Aortic valvular endografting also
offers a unique opportunity for hybrid procedures involving
great-vessel debranching and deployment of an endolumi-
nal graft into the aortic arch (Fig. 5).
An endovascular approach for aortic valve replacement
still presents several limitations that can be summarized as
follows:
(1) the size of the valve is limited by the delivery sheath di-
ameter, therefore, only small stented valves can be
implanted;
(2) the precise positioning of the stented valve onto the
aortic annulus or in supra-annular position is cumber-
some because it is very difficult to properly drive long
Figure 4 Schematic illustration of transapical aortic valve and stiff catheters into the arterial tree.
implantation. The prosthesis is being dilated at the annular
level within the native aortic valve cusps. Transapical sheath One potential solution is the off-pump trans left ventri-
insertion is secured with a purse-string suture. cle approach (Fig. 6).
Aortic valve surgery 173
Conflict of interest
None.